BUSINESS WIRE: Ipsen's DysportR approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics …

BUSINESS WIRE: Ipsen's DysportR approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada

09.04.2013, 07:30:03

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

o Launch expected in April 2013

PARIS & MONTREAL --(BUSINESS WIRE)-- 09.04.2013 --

Regulatory News:

Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for DysportR (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market DysportR for use in aesthetic medicine in Canada. Launch is expected in April 2013.

Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsen's group, stated: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind DysportR and to extend its geographical footprint. After its approval in 2009 in the United States, DysportRwill now be available in Canada for the treatment of glabellar lines."

About DysportR

The active substance in DysportR is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of muscular spasticity, including cervical dystonia (or spasmodic torticollis, a chronic condition in which the neck is twisted or deviated), spasticity of the upper/lower part of the body in adults after a stroke, dynamic equinus foot deformity in children with cerebral palsy, blepharospasm (involuntary contraction of the eyelids) and hemifacial spasm (involuntary contraction of the muscles located on one side of the face). DysportR was later developed for the treatment of a wide variety of neuromuscular disorders, as well as for use in aesthetic medicine. On 31 December 2012, DysportR had marketing authorizations in force in 75 countries. In Canada, DysportR has been approved for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age since June 12th, 2012.

Here is the original post:

BUSINESS WIRE: Ipsen's DysportR approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics ...